Careprost 3ml eye drops contains Bimatoprost which belongs to a group of medicines known as prostamides. It is an anti-glaucoma preparation, used to reduce high pressure in the eye. It may be used on its own or with other drops called beta-blockers which also reduce pressure. Eyes contain a clear, watery liquid that feeds the inside of the eye. Liquid is frequently being drained out of the eye and new liquid is made to replace this. If the liquid cannot drain out quickly, the pressure inside the eye builds up. Remove the contact lenses before applying this medicine.
Always use this medicine exactly as your doctor has directed you. This medicine should only be applied to the eye. This medicine may cause your eyelashes to darken and grow and cause the skin around the eyelid to darken too. The colour of your iris may become darker over time. These changes may be permanent. Consult your doctor for advice. It is not recommended for children and adolescents under the age of 18 years.
Uses of Careprost 3ml
Reduce pressure in the eyes in adults with glaucoma
How does Careprost Works?
Careprost works by increasing the amount of liquid that is drained which reduces the pressure inside the eye. If the high pressure is not reduced, it could lead to a disease called glaucoma and eventually damage your sight. It reduces intraocular pressure (IOP) in humans by causing an increase in outflow of the aqueous humor via the trabecular meshwork and uveoscleral pathways.
Side Effects of Careprost
Common Side Effects
- Longer eyelashes, slight redness and itchiness in eye
- Allergic reaction
- Headaches
- Dry, burning eyes
- Eye pain, tearing or irritation
Dosage of Careprost
Missed Dose
Overdose
Frequently Asked Questions
1. How does Careprost 3ml Eye Drops work?
Ans. Careprost 3ml Eye Drops contains Bimatoprost, which is a prostaglandin analogue. It is primarily used in treating high pressure in the eye. It works by increasing the production of aqueous humour (fluid in the eye) and reducing eye pressure.
Reviews
There are no reviews yet.